Answer
Although no interaction studies have been conducted with Cevenfacta (eptacog beta), clinical experience with other FVIIa-containing products indicates an elevated risk of thrombotic events when used simultaneously with activated prothrombin complex concentrates.
Sources for this answer
- CEVENFACTA 1 mg (45 KIU) powder and solvent for solution for injectionLFB Biopharmaceuticals Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 2Document updated
Sources checked